journal
MENU ▼
Read by QxMD icon Read
search

Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research

journal
https://www.readbyqxmd.com/read/27712720/a-systematic-review-of-health-economic-evaluation-studies-using-the-patient-s-perspective
#1
Bik-Wai Bilvick Tai, Yuna H Bae, Quang A Le
BACKGROUND: Patient-centered care has become increasingly important and relevant for informed health care decision making. OBJECTIVE: Our study aimed to perform a systematic review of health economic evaluation studies from the patient's perspective. METHODS: PubMed, EMBASE, and Cochrane Central databases were searched through May 2014 for cost-effectiveness, cost-utility, and cost-benefit studies using the patient's perspective in their analysis...
September 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27712719/economic-impact-of-integrated-care-models-for-patients-with-chronic-diseases-a-systematic-review
#2
Melissa Desmedt, Sonja Vertriest, Johan Hellings, Jochen Bergs, Ezra Dessers, Patrik Vankrunkelsven, Hubertus Vrijhoef, Lieven Annemans, Nick Verhaeghe, Mirko Petrovic, Dominique Vandijck
OBJECTIVES: To assess the costs and potential financial benefits of integrated care models for patients with chronic diseases, that is, type 2 diabetes mellitus, schizophrenia, and multiple sclerosis, respectively. METHODS: A systematic search of the literature was performed using EMBASE, MEDLINE, and Web of Science. Studies that conducted a cost analysis, considered at least two components of the chronic care model, and compared integrated care with standard care were included...
September 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27712718/a-comprehensive-algorithm-for-approval-of-health-technologies-with-without-or-only-in-research-the-key-principles-for-informing-coverage-decisions
#3
Karl Claxton, Stephen Palmer, Louise Longworth, Laura Bojke, Susan Griffin, Marta Soares, Eldon Spackman, Claire Rothery
BACKGROUND: The value of evidence about the performance of a technology and the value of access to a technology are central to policy decisions regarding coverage with, without, or only in research and managed entry (or risk-sharing) agreements. OBJECTIVES: We aim to outline the key principles of what assessments are needed to inform "only in research" (OIR) or "approval with research" (AWR) recommendations, in addition to approval or rejection. METHODS: We developed a comprehensive algorithm to inform the sequence of assessments and judgments that lead to different types of guidance: OIR, AWR, Approve, or Reject...
September 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27712717/did-it-matter-that-the-cancer-drugs-fund-was-not-nice-a-retrospective-review
#4
Padraig Dixon, Charlotte Chamberlain, William Hollingworth
BACKGROUND: The Cancer Drugs Fund (CDF) will have spent more than £1 billion between October 2010 and the introduction of reforms to its structure and operations in July 2016. There has been much more debate about the existence of the fund than about how it spent its substantial budget. It is important to undertake a retrospective examination of "where the money went" in light of the substantial reforms that will be introduced in 2016. OBJECTIVES: We review the means by which the CDF made recent funding decisions for cancer drugs to provide an assessment of the merits of the CDF "model" as a basis for allocation decisions...
September 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27712716/increasing-patient-involvement-in-drug-development
#5
Maria M Lowe, David A Blaser, Lisa Cone, Steve Arcona, John Ko, Rahul Sasane, Paul Wicks
BACKGROUND: To ensure the creation of treatments that maximize value at the lowest cost, all aspects of the health care system need to align with patient needs and preferences. Despite growing efforts to engage patients in research and regulatory activities, the pharmaceutical industry has yet to maximize patient involvement in the drug development process. OBJECTIVE: To gain a better understanding of the present state of patient involvement in drug development...
September 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27712715/financing-a-cure-for-diabetes-in-a-multipayer-environment
#6
Anirban Basu, Prasun Subedi, Sachin Kamal-Bahl
BACKGROUND: Financing medical breakthroughs or cures is becoming increasingly challenging in the current fiscal environment. OBJECTIVES: In this paper, we develop the precise conditions needed for a financing mechanism, HealthCoin, to work between a private payer and Medicare, to incentivize the former to invest in breakthrough therapies or cures in the US. METHODS: We illustrate the valuation of such a currency for a cure of Type 2 diabetes...
September 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27712714/development-and-validation-of-algorithms-to-identify-statin-intolerance-in-a-us-administrative-database
#7
Kathy L Schulman, Lois E Lamerato, Mehul R Dalal, Jennifer Sung, Mehul Jhaveri, Andrew Koren, Usha G Mallya, JoAnne M Foody
OBJECTIVES: To develop and validate algorithms to define statin intolerance (SI) in an administrative database using electronic medical records (EMRs) as the reference comparison. METHODS: One thousand adults with one or more qualifying changes in statin therapy and one or more previous diagnoses of hyperlipidemia, hypercholesterolemia, or mixed dyslipidemia were identified from the Henry Ford Health System administrative database. Data regarding statin utilization, comorbidities, and adverse effects were extracted from the administrative database and corresponding EMR...
September 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27712713/adherence-to-self-care-behaviors-among-patients-with-type-2-diabetes-the-role-of-risk-preferences
#8
Tzahit Simon-Tuval, Amir Shmueli, Ilana Harman-Boehm
OBJECTIVES: To examine whether the degree of risk aversion is associated with adherence to disease self-management among adults with type 2 diabetes. METHODS: This was a cross-sectional study of patients with type 2 diabetes (n = 408) aged 21 to 70 years who presented for routine visits in the diabetes clinic at a university medical center in Beer-Sheva, Israel. The authors used validated questionnaires to estimate adherence, risk preferences, motivation, self-efficacy, impulsivity, perceptions about the disease and the interpersonal process of care, and demographic and socioeconomic characteristics, in addition to retrieving data from computerized patient medical records of clinical indicators of disease severity...
September 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27712712/which-questionnaire-should-be-used-to-measure-quality-of-life-utilities-in-patients-with-acute-leukemia-an-evaluation-of-the-validity-and-interpretability-of-the-eq-5d-5l-and-preference-based-questionnaires-derived-from-the-eortc-qlq-c30
#9
Annemieke van Dongen-Leunis, W Ken Redekop, Carin A Uyl-de Groot
OBJECTIVES: The aim of this study was to assess the validity and interpretability of different preference-based questionnaires (generic 5-level EuroQol five-dimensional questionnaire [EQ-5D-5L], cancer-specific Quality of Life Questionnaire Preference-Based Measure, and European Organization of Randomized Controlled Trials 8 Dimension [EORTC-8D]) in patients with acute leukemia. METHODS: Patients who participated in Hemato-Oncologie voor Volwassenen Nederland (HOVON - the Haemato Oncology Foundation for Adults in the Netherlands) clinical trials between 1999 and 2011 at a single hospital were invited to complete the questionnaires...
September 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27712711/comparison-of-daily-versus-weekly-recording-of-gastroesophageal-reflux-disease-symptoms-in-patients-with-a-partial-response-to-proton-pump-inhibitor-therapy
#10
Anna Rydén, Olivia C Leavy, Katarina Halling, Arthur A Stone
BACKGROUND: The Reflux Symptom Questionnaire electronic Diary (RESQ-eD) and the Reflux Symptom Questionnaire 7-day recall (RESQ-7) are versions of a patient-reported outcome instrument that was developed and validated for measuring the frequency and intensity of symptoms in patients with gastroesophageal reflux disease (GERD) who have a partial response to proton pump inhibitor (PPI) therapy. OBJECTIVE: The aim of these analyses was to assess the ability of the RESQ-7 to reproduce findings based on RESQ-eD reports of the same symptoms...
September 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27712710/measuring-health-and-broader-well-being-benefits-in-the-context-of-opiate-dependence-the-psychometric-performance-of-the-icecap-a-and-the-eq-5d-5l
#11
Ilias Goranitis, Joanna Coast, Ed Day, Alex Copello, Nick Freemantle, Jennifer Seddon, Carmel Bennett, Emma Frew
BACKGROUND: Measuring outcomes in economic evaluations of social care interventions is challenging because both health and well-being benefits are evident. The ICEpop CAPability instrument for adults (ICECAP-A) and the five-level EuroQol five-dimensional questionnaire (EQ-5D-5L) are measures potentially suitable for the economic evaluation of treatments for substance use disorders. Evidence for their validity in this context is, however, lacking. OBJECTIVES: To assess the construct validity of the ICECAP-A and the EQ-5D-5L in terms of convergent and discriminative validity and sensitivity to change on the basis of standard clinical measures (Clinical Outcomes in Routine Evaluation-Outcome Measure, Treatment Outcomes Profile, Interpersonal Support Evaluation List, Leeds Dependence Questionnaire, and Social Satisfaction Questionnaire)...
September 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27712709/cost-effectiveness-of-rotavirus-vaccination-in-france-accounting-for-indirect-protection
#12
Dan Yamin, Katherine E Atkins, Vanessa Remy, Alison P Galvani
BACKGROUND: Vaccination against rotavirus has shown great potential for reducing the primary cause of severe childhood gastroenteritis. Previous economic evaluations of rotavirus vaccination in France have not modeled the potential impact of vaccines on disease burden via reduced transmission. OBJECTIVE: To determine the cost-effectiveness of the introduction of pentavalent rotavirus vaccination into the French infant vaccination schedule. METHODS: We developed an age-structured model of rotavirus transmission calibrated to 6 years of French gastroenteritis incidence and vaccine clinical trial data...
September 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27712708/patient-heterogeneity-in-health-economic-decision-models-for-chronic-obstructive-pulmonary-disease-are-current-models-suitable-to-evaluate-personalized-medicine
#13
Martine Hoogendoorn, Talitha L Feenstra, Yumi Asukai, Andrew H Briggs, Sixten Borg, Roberto W Dal Negro, Ryan N Hansen, Sven-Arne Jansson, Reiner Leidl, Nancy Risebrough, Yevgeniy Samyshkin, Margarethe E Wacker, Maureen P M H Rutten-van Mölken
OBJECTIVES: To assess how suitable current chronic obstructive pulmonary disease (COPD) cost-effectiveness models are to evaluate personalized treatment options for COPD by exploring the type of heterogeneity included in current models and by validating outcomes for subgroups of patients. METHODS: A consortium of COPD modeling groups completed three tasks. First, they reported all patient characteristics included in the model and provided the level of detail in which the input parameters were specified...
September 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27712707/the-capability-approach-a-critical-review-of-its-application-in-health-economics
#14
Milad Karimi, John Brazier, Hasan Basarir
The capability approach is an approach to assessing well-being developed by Amartya Sen. Interest in this approach has resulted in several attempts to develop questionnaires to measure and value capability at an individual level in health economics. This commentary critically reviews the ability of these questionnaires to measure and value capability. It is argued that the method used in the questionnaires to measure capability will result in a capability set that is an inaccurate description of the individual's true capability set...
September 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27712706/impact-of-treatment-subsidies-and-cash-payouts-on-treatment-choices-at-the-end-of-life
#15
Eric Finkelstein, Chetna Malhotra, Junxing Chay, Semra Ozdemir, Akhil Chopra, Ravindran Kanesvaran
OBJECTIVES: To examine the extent to which financial assistance, in the form of subsidies for life-extending treatments (LETs) or cash payouts, distorts the demand for end-of-life treatments. METHODS: A discrete choice experiment was administered to 290 patients with cancer in Singapore to elicit preferences for LETs and only palliative care (PC). Responses were fitted to a latent class conditional logistic regression model. We also quantified patients' willingness to pay to avoid and willingness to accept a less effective LET or PC-only...
September 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27712705/first-and-foremost-battle-the-virus-eliciting-patient-preferences-in-antiviral-therapy-for-hepatitis-c-using-a-discrete-choice-experiment
#16
Axel Mühlbacher, Susanne Bethge
BACKGROUND: There has been tremendous progress regarding treatment options for hepatitis C virus (HCV) infection. Several interferon-free regimens are awaiting regulatory approval. These innovations promise substantial reductions in the burden of disease and side effects as well as a decrease in treatment duration. OBJECTIVES: The aim of this quantitaitive study was to elicit patient preferences for attributes of innovative antiviral therapies for hepatitis C. METHODS: A systematic literature search and 14 semi-structured interviews were performed, resulting in eight patient-relevant characteristics...
September 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27712704/measuring-high-risk-patients-preferences-for-pharmacogenetic-testing-to-reduce-severe-adverse-drug-reaction-a-discrete-choice-experiment
#17
Di Dong, Semra Ozdemir, Yong Mong Bee, Sue-Anne Toh, Marcel Bilger, Eric Finkelstein
OBJECTIVES: To investigate patient preferences and willingness to pay (WTP) for a genetic test that can reduce the risk of life-threatening adverse drug reactions (ADRs). We hypothesize that test features (risk of developing the adverse reaction with and without testing, test cost, and treatment cost) and the choice context (physician recommendation and the most common choice made by peer patients) will influence choices. METHODS: A discrete choice experiment was conducted in which 189 patients at high risk for gout were asked to choose between treatment options that varied along key attributes...
September 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27712703/attribute-development-using-continuous-stakeholder-engagement-to-prioritize-treatment-decisions-a-framework-for-patient-centered-research
#18
Susan dosReis, Wendy Camelo Castillo, Melissa Ross, Marcy Fitz-Randolph, Angela Vaughn-Lee, Beverly Butler
OBJECTIVES: To develop a methodological approach for selecting, validating, and prioritizing attributes for health care decision making. METHODS: Participants (n = 48) were recruited from community support groups if they had a child aged 26 years or younger diagnosed with a coexisting mental health condition and cognitive impairment. Six in-depth interviews eliciting care management experiences were transcribed and coded into themes following the principles of grounded theory and the constant comparative method...
September 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27712702/developing-a-patient-centered-benefit-risk-survey-a-community-engaged-process
#19
Ilene L Hollin, Caroline Young, Caroline Hanson, John F P Bridges, Holly Peay
OBJECTIVES: To provide a community-engaged process to inform the design of a stated-preferences experiment. The process involved integrating patients and caregivers of people with Duchenne/Becker muscular dystrophy, advocates, clinicians, and the sponsor in conceptualizing and developing a benefit-risk survey on the basis of phase III trial results. METHODS: Our community-engagement process for the development of a stated-preference survey included a set of five guiding principles with a foundation in the principles of community-engaged research...
September 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27712701/a-framework-for-incorporating-patient-preferences-regarding-benefits-and-risks-into-regulatory-assessment-of-medical-technologies
#20
Martin Ho, Anindita Saha, K Kimberly McCleary, Bennett Levitan, Stephanie Christopher, Kristen Zandlo, R Scott Braithwaite, A Brett Hauber
BACKGROUND: In response to 2012 guidance in which the US Food and Drug Administration's (FDA) Center for Devices and Radiological Health (CDRH) stated the importance of patient-centric measures in regulatory benefit-risk assessments, the Medical Device Innovation Consortium (MDIC) initiated a project. The project was used to develop a framework to help the Food and Drug Administration (FDA) and industry sponsors understand how patient preferences regarding benefit and risk might be integrated into the review of innovative medical devices...
September 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
journal
journal
34615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"